Dermasensor Skin Lesion Assessment

Skin cancer remains the most common cancer in the United States, with over 5 million cases diagnosed annually. While those numbers are sobering, there is a powerful silver lining: when melanoma is detected early, the 5-year survival rate exceeds 99%.

Making early evaluation a priority is no longer just a recommendation—it’s a lifesaver. That is why Dr. Yuri Choi and the team at IT Intelligent Treatment are proud to offer DermaSensor, an FDA-cleared handheld device designed to help physicians evaluate suspicious skin lesions in seconds.

The Science Behind the Scan: AI-Powered Precision

DermaSensor represents a leap forward in dermatologic technology. Instead of relying solely on the naked eye, this device utilizes AI-powered optical spectroscopy to analyze cellular patterns beneath the skin’s surface.

Proven Clinical Accuracy

Clinical research rigorously supports the efficacy of DermaSensor in a clinical setting:

• A multicenter study of over 1,500 skin lesions showed 96% sensitivity for detecting skin cancers compared to traditional biopsy.
• Dermatology studies report sensitivity approaching 97% for melanoma, basal cell, and squamous cell carcinoma.

Personalized Care by Dr. Yuri Choi, MD

Technology is most effective when guided by expertise. Each DermaSensor assessment is performed and reviewed by Dr. Yuri Choi, an internist and longevity physician. Dr. Choi provides a comprehensive evaluation, offering clear guidance on whether a dermatology referral or further testing is appropriate.

Who Should Consider a DermaSensor Scan?

You should consider an evaluation if you notice:

• A new mole or unusual skin spot.
• A mole that has changed in size, shape, or color.
• A lesion that bleeds, crusts, or fails to heal.
• The “Ugly Duckling”—any spot that looks different from the others.